Glynn CJ, Lloyd JW. Biochemical changes associated with intractable pain. Br Med J. 1978;1:280–1.
Mellor DJ, Stafford KJ, Todd SE, et al. A comparison of catecholamine and cortisol responses of young lambs and calves to painful husbandry procedures. Aust Vet J. 2002;80:228–33.
Moore RA, Evans PJ, Smith RF, et al. Increased cortisol excretion in chronic pain. Anesthesia. 1983;38:788–91.
Nakagawa H, Hosokawa R. Study of the stress response to acute pain in the awake human. Pain Clin. 1994;7:317–24.
Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am. 2000;26:989–1002.
Neeck G, Federlin K, Graef V, et al. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol. 1990;17:24–9.
Shenkin HA. Effect of pain on diurnal pattern of plasma corticoid levels. Neurology. 1964;14:1112–7.
Straub RH, Cutolo M. Involvement of the hypothalamic–pituitary–adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 2001;44:493–507.
Strittmatter M, Bianchi O, Ostertag D, et al. Altered function of the hypothalamic–pituitary–adrenal axis in patients with acute, chronic and episodic pain. Schmerz. 2005;19:109–16 (Article in German).
Tennant F. Intractable pain is a severe stress state associated with hypercortisolemia and reduced adrenal reserve. Drug Alcohol Depend. 2000;60(Suppl. 1):220–1.
Yoshihara T, Shigeta K, Hasegawa H, et al. Neuroendocrine responses to psychological stress in patients with myofascial pain. J Orofac Pain. 2005;19:202–8.
Griep EN, Boersma JW, Lentjes EG, et al. Function of the hypothalamic–pituitary–adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998;25:1374–81.
Akil H, Shiomi H, Mathews J. Induction of the intermediate pituitary by stress: synthesis and release of a non-opioid form of B-endorphin. Science. 1985;227:424–8.
Chikanza IC, Petrou P, Kingsley G, et al. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum. 1992;35:1281–8.
Cutolo M, Foppiani L, Prete C, et al. Hypothalamic–pituitary–adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J Rheumatol. 1999;26:282–8.
Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–62.
Bateman A, Singh A, Kral T, et al. The immune–hypothalamic–pituitary adrenal axis. Endocr Rev. 1989;10:92–112.
McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural endocrine and immune interactions. Brain Res Rev. 1997;23:79–133.
McEwen BS, de Kloet ER, Rostene W. Adrenal steroid receptors and action in the nervous system. Physiol Rev. 1986;66:1121–88.
Jorgensen C, Bressot N, Bologn C, et al. Dysregulation of the hypothalamic-pituitary axis in rheumatoid arthritis. J Rheum. 1995;22:1829–33.
Dons RF, Shaki KM. Changes in triidothyronine mark severe pain syndrome: a case report. Military Med. 1994;159:465–6.
Edmondson EA, Bonnet KA, Friedhoff AJ. The effect of hyperthyroidism on opiate receptor binding and pain sensitivity. Life Sci. 1990;47:2283–9.
Aloisi AM, Buonocore M, Merlo L, et al. Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment. Psychoneuroendocrinology. 2011;36:1032–9.
Atkinson JH Jr, Kremer EF, Ward HW, et al. Pre- and post-dexamethasone saliva cortisol determination in chronic pain patients. Biol Psychiatry. 1984;19:1155–9.
Matoushek TA, Kearney TC, Lindsay TS, et al. Loss of antinociceptive effectiveness of morphine and oxycodone following titration of levothyroxine: case reports and a brief review of published literature. J Opioid Manag. 2012;8:193–6.
Sonkin L. Therapeutic trials with thyroid hormones in chemically euthyroid patients with myofascial pain and complaints suggesting mild thyroid insufficiency. J Back Musculoskelet Rehabil. 1997;8(2):165–71.
Russell U. Neurohormonal aspects of fibromyalgia syndrome. Rheum Dis Clin North Am. 1989;15:149–68.
Pillemer SR, Bradley LA, Crofford LJ, et al. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum. 1997;40:1928–39.
Tennant F, Hermann L. Normalization of serum cortisol concentration with opioid treatment of severe chronic pain. Pain Med. 2002;3:132–4.
Tennant F, Hermann L. Using biologic markers to identify legitimate chronic pain. Am Clin Lab. 2002;21(5):14–5, 18.
Pednekar J, Mulgaonker VK. Role of testosterone on pain threshold in rats. Indian J Physiol Pharmacol. 1995;39:423–4.
Fischer L, Clemente JT, Tambeli CH. The protective role of testosterone in the development of temporomandibular joint pain. J Pain. 2007;8:437–42.
Forman IJ, Tingle V, Estilow S, Caler J. The response to analgesia testing is affected by gonadal steroids in the rat. Life Sci. 1989;45:447–54.
Grossman A, Gaillard RC, McCartney P, et al. Opiate modulation of the pituitary–adrenal axis: effects of stress and circadian rhythm. Clin Endocrin. 1982;17:279–86.
Guth L, Zhang Z, Roberts E. Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury. Proc Natl Acad Sci. 1994;91:308–12.
Harbuz MS, Perveen-Gill Z, Lightman SL, et al. A protective role for testosterone in adjuvant-induced arthritis. Br J Rheumatol. 1995;34:1117–22.
Long JB, Holaday JW. Blood–brain barrier: endogenous modulation by adrenal–cortical function. Science. 1985;227:1580–3.
Wu FS, Gibbs TT, Farb DH. Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-d-aspartate receptor. Mol Pharmacol. 1991;40:333–6.
Orchinik M, Murray TF, Moore FL. A corticosteroid receptor in neuronal membranes. Science. 1991;252:1848–51.
Orstavil K, Morheim I, Jorum E. Pain and small fiber neuropathy in patients with hypothyroidism. Neurology. 2006;67:786–91.
Ren K, Wei F, Dubner R, et al. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: involvement of spinal NMDA receptor mechanisms. Brain Res. 2000;865:272–7.
Stafford EC, Ulibarri CM, Falk JE, et al. Gonadal hormone modulation of mu, kappa, and, delta opioid antinociception in male and female rats. J Pain. 2006;6:261–74.
Holaday JW, Law PY, Loli HH, et al. Adrenal steroids indirectly modulate morphine and betaendorphin effects. J Pharmacol Exp Ther. 1979;208:176–83.
Joels M, DeKloet E. Control of neuronal excitability by corticosteroid hormones. Trends Neurosci. 1992;15:25–30.
Kibaly C, Meyer L, Patte-Mensah C, Mensah-Nyagan AG. Biochemical and functional evidence for the control of pain mechanisms by dehydroepiandrosterone endogenously synthesized in the spinal cord. FASEB J. 2008;22:93–104.
Lentjes EG, Griep EN, Boersma JW, Romijn FP, de Kloet ER. Glucocorticoid receptors, fibromyalgia, and low back pain. Psychoneuroendocrinology. 1997;22:603–14.
Leonelli E, Bianchi R, Cavaletti G, et al. Progesterone and its derivatives are neuro-protective agents in experimental diabetic neuropathy: a multi-modal analysis. Neuroscience. 2007;144:1293–304.
Jain R, Zwickler D, Hollander CS, et al. Corticotropin-releasing factor modulates the immune response to stress in the rat. Endocrinology. 1991;128:1329–36.
Mensah-Nyagan AG, Meyer L, Schaeffer V, Kibaly C, Patte-Mensah C. Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology. 2009;34(Suppl. 1):S169–77.
Aloisi AM, Ceccarelli I, Fiorenzani P, et al. Testosterone affects pain-related responses differently in male and female rats. Neurosci Lett. 2004;361:262–4.
Aloisi AM, Bonifazi M. Sex hormones, central nervous system and pain. Horm Behav. 2006;50:1–7.
Ceccon M, Runbaugh G, Vicini S. Distinct effect of pregnenolone sulfate on NMDA receptor suptypes. Neuropharmocology. 2001;40:491–500.
Dawson-Basoa M, Gintzler AR. Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain. 1996;64:608–15.
Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94:557–72.
Horner HC, Packan DR, Sapolsky RM. Glucocorticoids inhibit glucose transport in cultured hippocampal neurons and glia. Neuroendocrinology. 1990;52:57–63.
Jones KJ. Gonadal steroids and neuronal regeneration: a therapeutic role. Adv Neurol. 1993;59:227–40.
Kimonides VG, Khatibi NH, Svendsen CN, et al. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA. 1998;95:1852–7.
Mayo W, Le Moal M, Abrous DN. Pregnenolone sulfate and aging of cognitive functions: behavioral; neurochemical, and morphological investigations. Horm Behav. 2001;40:215–7.
McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev. 1988;4:17–30.
Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev. 1984;5:25–44.
Penza P, Lombardi R, Camozzi F, et al. Painful neuropathy in subclinical hypothyroidism: clinical and neuropathological recovery after hormone replacement therapy. Neurol Sci. 2009;30:149–51.
Schlechte JA, Sherman BM. Decreased glucocorticoids receptor binding in adrenal insufficiency. Clin Endocrinol Metab. 1982;54:145–9.
Wiegers GJ, Reul JM. Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci. 1998;19:317–21.
Tennant F. How to use adrenocorticotropin as a biomarker in pain management. Pract Pain Manag. 2012;12:62–6.
Khorami S, Muniyappa R, Nackers L, et al. Effect of chronic osteoarthritis pain on neuroendocrine function in men. Clin Endocrinol Metab. 2006;11:4313–8.
Abs R, Verhelst J, Maeysaert J, et al. Endocrine consequences of long term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–22.
Daniell HW. DHEA deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901–7.
Daniel HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.
Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.
Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs in animal and human endocrine systems. Endocr Rev. 2010;31:98–132.
Elliott JA, Horton E, Fibuch EE. The endocrine effects of long-term oral opioid therapy: a case report and review of the literature. J Opioid Manag. 2011;7:145–54.
Finch PM, Roberts LJ, Price L, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251–4.
Roberts LJ, Finch PM, Pullan PT, et al. Sex hormone suppression by intrathecal opioids: a prospective study. Clin J Pain. 2002;18:144–8.
Rubinstein AL, Carpenter DM, Minkoff J. Hypogonadism in men using daily opioid therapy for non-cancer pain is associated with duration of action of opioid. Poster presentation at the 2012 Annual Meeting of the American Academy of Pain Medicine, February 23–26, 2012; Palm Springs; Abstract #229.
Tennant F. Hormone therapies: newest advance in pain care. Pract Pain Manag. 2011;11:98–105.
Arnold G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing Syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593–602.
Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing Syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.
Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing Syndrome. Ann Intern Med. 2003;138:980–91.
Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222–7.
Krakoff L. Glucocorticoid excess syndromes causing hypertension. Cardiol Clin. 1988;6:537–45.
Tennant F. Complications of uncontrolled, persistent pain. Pract Pain Manag. 2004;4(1):11–14.
Newell-Price J, Bertango X, Grossman AB, et al. Cushing’s Syndrome. Lancet. 2006;367:1605–17.
Addison T. On the constitutional and local effects of disease of the supra-renal capsules. Samuel Highley, London (1855).
Tennant F. Hormone testing and replacement in pain patients made simple. Pract Pain Manag. 2012;12:54–62.
Tennant F. Corticotropin (ACTH) and cortisol serum concentrations help predict high dose opioids requirements. PAINWeek® 2012 national conference on pain for frontline practitioners, Abstract 119.